The effect of sarpogrelate compared to aspirin in high- or very-high-risk diabetes for primary prevention.

0.1%), although the difference did not reach statistical significance (Table 2 ).

also in 111,027 other papers

Among the components of the efficacy endpoint, there was borderline significant reduction in all-cause death but no difference in myocardial infarction (MI) or stroke.

also in 11,409 other papers

However, sarpogrelate showed a trend toward a lower hazard of NACE in men compared to women (P interaction = 0.069) and individuals with DM retinopathy compared with those without (P interaction = 0.124).

also in 53,322 other papers